Examining the evidence for weight management in individuals with type 2 diabetes

被引:9
作者
Garvey, W. Timothy [1 ]
Umpierrez, Guillermo E. [2 ]
Dunn, Julia P. [3 ]
Kwan, Anita Y. M. [3 ]
Varnado, Oralee J. [3 ]
Konig, Manige [3 ]
Levine, Joshua A. [3 ]
机构
[1] Univ Alabama Birmingham, UAB Diabet Res Ctr, Birmingham, AL USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
antidiabetic drug; antiobesity drug; obesity therapy; type; 2; diabetes; weight control; LIFE-STYLE INTERVENTION; GLP-1 RECEPTOR AGONISTS; CLINICAL-PRACTICE GUIDELINES; GLUCAGON-LIKE PEPTIDE-1; AMERICAN ASSOCIATION; GLYCEMIC CONTROL; OBESE-PATIENTS; DOUBLE-BLIND; BODY-WEIGHT; MEDICATION ADHERENCE;
D O I
10.1111/dom.14764
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The obesity epidemic has been linked to the worsening diabetes epidemic. Despite this, weight reduction for individuals with obesity is seen as a secondary, or even tertiary, consideration in the treatment of type 2 diabetes (T2D). The aim of this review is to examine the benefits of weight management in individuals with T2D. A literature review of current available published data on the benefits of weight reduction in individuals with T2D was conducted. In individuals with T2D who have obesity or overweight, modest and sustained weight reduction results in improvement in glycaemic control and decreased utilization of glucose-lowering medication. A total body weight loss of 5% or higher reduces HbA1c levels and contributes to mitigating risk factors of cardiovascular disease, such as hyperlipidaemia and hypertension, as well as other disease-related complications of obesity. Progressive improvements in glycaemic control and cardiometabolic risk factors can occur when the total body weight loss increases to 10% or more. In the approach to treating patients with T2D and obesity, prioritizing weight management and the use of therapeutics that offer glycaemic control as well as the additional weight loss should be emphasized given their potential to attenuate the progression and severity of T2D.
引用
收藏
页码:1411 / 1422
页数:12
相关论文
共 129 条
[1]   MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study [J].
Ambery, Philip ;
Parker, Victoria E. ;
Stumvoll, Michael ;
Posch, Maximilian G. ;
Heise, Tim ;
Plum-Moerschel, Leona ;
Tsai, Lan-Feng ;
Robertson, Darren ;
Jain, Meena ;
Petrone, Marcella ;
Rondinone, Cristina ;
Hirshberg, Boaz ;
Jermutus, Lutz .
LANCET, 2018, 391 (10140) :2607-2618
[4]   Glycemic Targets: Standards of Medical Care in Diabetes-2018 [J].
不详 .
DIABETES CARE, 2018, 41 :S55-S64
[5]   9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 [J].
American Diabetes Association Professional Practice Committee .
DIABETES CARE, 2022, 45 :S125-S143
[6]   Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Gastric Bypass, Sleeve Gastrectomy, and Usual Care [J].
Aminian, Ali ;
Wilson, Rickesha ;
Zajichek, Alexander ;
Tu, Chao ;
Wolski, Kathy E. ;
Schauer, Philip R. ;
Kattan, Michael W. ;
Nissen, Steven E. ;
Brethauer, Stacy A. .
DIABETES CARE, 2021, 44 (11) :2552-2563
[7]   Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure [J].
Aminian, Ali ;
Vidal, Josep ;
Salminen, Paulina ;
Still, Christopher D. ;
Nor Hanipah, Zubaidah ;
Sharma, Gautam ;
Tu, Chao ;
Wood, G. Craig ;
Ibarzabal, Ainitze ;
Jimenez, Amanda ;
Brethauer, Stacy A. ;
Schauer, Philip R. ;
Mahawar, Kamal .
DIABETES CARE, 2020, 43 (03) :534-540
[8]   Medical and surgical management of obesity and diabetes: what's new? [J].
Ammori, B. J. ;
Skarulis, M. C. ;
Soran, H. ;
Syed, A. A. ;
Eledrisi, M. ;
Malik, R. A. .
DIABETIC MEDICINE, 2020, 37 (02) :203-210
[9]  
[Anonymous], 2020, ONCE WEEKLY SEMAGLUT
[10]  
[Anonymous], 2021, TIRZEPATIDE ACHIEVED